David Meek­er starts the next chap­ter of his long biotech ca­reer as chair­man of the board

David Meek­er may be leav­ing Sanofi Gen­zyme af­ter a long run at the big Boston op­er­a­tion, but he’s stay­ing in biotech.

Meek­er re­cent­ly an­nounced his re­tire­ment from the Sanofi sub­sidiary, ef­fec­tive in June, and to­day he’s tak­ing the chair­man’s role at Rhythm, a Boston-based start­up that is de­vel­op­ing pep­tide ther­a­pies for rare ge­net­ic con­di­tions.

Meek­er is fol­low­ing a path blazed by for­mer boss Hen­ri Ter­meer, who fol­lowed the $20 bil­lion sale of Gen­zyme with a high-pro­file role seed­ing biotech star­tups and serv­ing on a va­ri­ety of boards in the hot life sci­ences hub.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER